SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* MARR TECHNOLOGIES BV (Last) (First) (Middle) STRAWINSKYLAAN 1431 1077XX (Street) AMSTERDAM THE NEDTHERLANDS P7 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol CALYPTE BIOMEDICAL CORP [ CBMC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 04/04/2005
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, Anti-dilution Adjustment	06/30/2005		J(4)		1,968,750	A	$0.00(4)	1,968,750	D(1)
Common Stock	07/21/2006		P		16,964,583	A	$0.15	16,964,583	D(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant to Purchase Common Stock	$0.325	04/04/2005		J(2)		9,333,333		04/04/2005	04/03/2010	Common Stock	9,333,333	(2)	0	D(1)
Warrant to Purchase Common Stock	$0.325	04/04/2005		J(2)		4,200,000		04/04/2005	04/03/2010	Common Stock	4,200,000	(2)	0	D(1)
Warrant to Purchase Common Stock	$0.4	04/04/2005		J(3)		500,000		04/04/2005	04/03/2010	Common Stock	500,000	(3)	0	D(1)
Convertible Notes	$0.3	04/04/2005		J(2)		2,800,000		04/04/2005	04/03/2007	Common Stock	9,333,333	(2)	2,800,000	D(1)
Warrant to Purchase Common Stock	$0.325	06/30/2005		J(4)		306,250		06/30/2005	05/28/2009	Common Stock	9,333,333	(4)	0	D(1)
Warrant to Purchase Common Stock	$0.45	06/30/2005		J(5)		2,625,000		06/30/2005	05/28/2009	Common Stock	4,200,000	(5)	0	D(1)
Warrant to Purchase Common Stock	$0.25	08/03/2006		J(6)		8,482,292		08/03/2006	08/03/2007	Common Stock	8,482,292	(6)	8,482,292	D(1)

Explanation of Responses:

1. The direct owner is Marr Technologies BV, which is a wholly owned subsidiary of Marr Technologies NV, which is a wholly owned subsidiary of Marr Technologies Limited, which is a wholly owned subsidiary of Marr Group Holdings Limited, which is controlled by Marat R. Safin. Marr Technologies NV, Marr Technologies Limited, Marr Group Holdings Limited and Marat R. Safin are indirect beneficial owners of the reported securities.

2. Marr Technologies BV purchased 8% convertible promissory notes of HIV, due April 3, 2007, in the aggregate principal amount of $2,800,000. These notes are convertible into common stock of HIV at an exercise price of $0.30 per share. As an inducement to purchase these notes, the Company issued Marr Technologies a warrant to purchase 9,333,333 shares of common stock of HIV and a warrant to purchase 4,200,000 shares of common stock of HIV.

3. Marr Technologies BV was issued a warrant to purchase 500,000 shares of common stock of HIV in exhange for providing HIV a $5.5 million credit facility.

4. Marr Technologies BV was issued 1,968,750 shares of common stock of HIV and warrants to purchase 306,250 shares of common stock of HIV as a result of certain anti-dilution provisions from an equity financing that occurred in April and July of 2004.

5. Marr Technologies BV received this warrant to replace an existing warrant to purchase 2,625,000 shares of common stock of CYPT for $0.50 per share.

6. Marr Technologies BV received this warrant to purchase common stock of HIV in consideration for exercising, in full, five other warrants held by Marr Technologies in HIV.

Remarks:

Exhibit A - Joint Filer Information

	Christian Strik	10/10/2006
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.